Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Vyome Holdings, Inc. (HIND : NSDQ)

• Company Description    Vyome Therapeutics Inc. is a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases principally in the US. Vyome Therapeutics Inc., formerly known as ReShape Lifesciences Inc., is based in CAMBRIDGE, Mass. Number of Employees: 18

• Price / Volume Information    Yesterday's Closing Price: $7.54 Daily Weekly Monthly 20 Day Moving Average: 75,571 shares Shares Outstanding: 0.67 (millions) Market Capitalization: $5.08 (millions) Beta: 1.02 52 Week High: $1,028.92 52 Week Low: $7.27 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -51.91% -52.78% 12 Week -26.37% -33.15% Year To Date -98.31% -98.49%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 18 Technology Dr Suite 110 - Irvine,CA 92618 USA ph: 949-429-6680 fax: - ir@reshapelifesci.com http://www.reshapelifesciences.com

• General Corporate Information    Officers Paul F. Hickey - President and Chief Executive Officer Dan W. Gladney - Executive Chairman of the Board Thomas Stankovich - Senior Vice President and Chief Financial Officer Lori McDougal - Director Arda Minocherhomjee - Director Peer Information Vyome Holdings, Inc. (GSAC) Vyome Holdings, Inc. (CASI) Vyome Holdings, Inc. (ALCD.) Vyome Holdings, Inc. (OMNN) Vyome Holdings, Inc. (CGPI.) Vyome Holdings, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 92943X104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/13/25 Share - Related Items Shares Outstanding: 0.67 Most Recent Split Date: 8.00 (0.25:1) Beta: 1.02 Market Capitalization: $5.08 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.77 Price/Cash Flow: - Price / Sales: 0.79 EPS Growth vs. Year Ago Period: 97.42% vs. Previous Quarter: -111.85% Sales Growth vs. Year Ago Period: -36.79% vs. Previous Quarter: 11.59% ROE 06/30/25 - -216.95 03/31/25 - -251.90 12/31/24 - -323.98 ROA 06/30/25 - -69.42 03/31/25 - -59.49 12/31/24 - -113.93 Current Ratio 06/30/25 - 2.77 03/31/25 - 1.53 12/31/24 - 0.92 Quick Ratio 06/30/25 - 1.97 03/31/25 - 0.91 12/31/24 - 0.43 Operating Margin 06/30/25 - -69.71 03/31/25 - -48.26 12/31/24 - -89.06 Net Margin 06/30/25 - -69.71 03/31/25 - -48.26 12/31/24 - -89.06 Pre-Tax Margin 06/30/25 - -69.33 03/31/25 - -47.82 12/31/24 - -88.57 Book Value 06/30/25 - 9.77 03/31/25 - 10.91 12/31/24 - -34.66 Inventory Turnover 06/30/25 - 0.92 03/31/25 - 0.93 12/31/24 - 0.97 Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - - Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - -

Powered by Zacks Investment Research ©